The Cost-Effectiveness of Infliximab Is Different in Ulcerative Colitis and Crohn's Disease: Markov Model in a Population-Based Incident Patient Cohort

Selwyn H. Odes, Dan Greenberg, Hillel Vardi, Michael Friger, Reinhold W. Stockbrugger, Ebbe Langholz, Pia Munkholm

Research output: Contribution to journalMeeting Abstractpeer-review

Fingerprint

Dive into the research topics of 'The Cost-Effectiveness of Infliximab Is Different in Ulcerative Colitis and Crohn's Disease: Markov Model in a Population-Based Incident Patient Cohort'. Together they form a unique fingerprint.

Medicine & Life Sciences